Global health technology company driving medical imaging, smart catheter systems, connected health platforms, and AI-powered clinical decision tools across 64 H2020 projects.
Philips Electronics Nederland is the R&D arm of Royal Philips, a global health technology company headquartered in Eindhoven. In H2020, they focus on medical imaging systems (MRI, PET, ultrasound), smart catheter technologies, connected health platforms for chronic disease management, and AI-driven clinical decision support. They bring deep hardware-software integration expertise — from micro-fabricated medical devices to population health analytics — bridging the gap between clinical research and industrial-scale medical product development.
Projects like HYPMED (hybrid PET/MRI for breast cancer), InForMed (micro-fabricated medical devices), ASTONISH (smart optical imaging), FBI (bio-photonic imaging), and InSPECT (integrated spectrometers) demonstrate deep, sustained imaging expertise.
CHESS, ProACT, REACH2020, iManageCancer, HEART, and AffecTech all address remote patient monitoring, chronic disease self-management, and IoT-based health activity recognition.
Multiple recent projects reference smart catheters, open platforms for catheter labs, IVUS, FFR, and ICE — indicating a strong push into interventional cardiology technology.
Recent keywords like trustworthy AI, big data technologies, population health management, and projects like SODA (oblivious data analytics) show growing investment in AI-driven health analytics.
SUPERCLOUD, SCOTT (secure connected things), and ENABLE-S3 (automated systems validation) reflect capability in security, cloud infrastructure, and IoT trustworthiness.
PolyCE (post-consumer recycled polymers for electronics) shows early engagement with circular economy for consumer electronics and WEEE recycling.
In the early H2020 period (2015–2018), Philips concentrated on medical imaging fundamentals (PET/MRI, spectral tissue sensing), connected health for chronic disease management, and smart production/supply chain digitization. From 2018 onward, the focus shifted decisively toward AI-driven healthcare (trustworthy AI, big data, population health management), interventional cardiology devices (smart catheters, open catheter lab platforms), and advanced diagnostics like liquid biopsy and molecular pathway modeling. The trajectory shows a company moving from diagnostic hardware toward integrated AI-powered clinical decision systems.
Philips is converging its imaging, catheter, and AI capabilities into integrated interventional healthcare platforms — expect future projects to combine real-time AI guidance with minimally invasive procedures.
Philips predominantly joins consortia as a participant (50 of 64 projects) rather than leading them, but when they coordinate (10 projects), they take on technically ambitious work like InForMed (EUR 2M+, pilot line for medical devices) and SODA (scalable data analytics). With 1,070 unique consortium partners across 37 countries, they function as a major hub — their sheer network breadth means partnering with Philips opens doors to a vast web of European research groups and companies. They favor large, multi-partner RIA and ECSEL consortia, which reflects their role as an industrial anchor bringing scale-up and commercialization credibility.
Philips has collaborated with 1,070 unique partners across 37 countries, making them one of the most connected industrial players in H2020 health technology. Their network spans nearly all EU member states and associated countries, with particularly strong ties to university hospitals, medical research institutes, and electronics manufacturers.
Philips is one of very few organizations that can span the entire chain from fundamental medical imaging research to industrial-scale device manufacturing within a single entity. Unlike university labs that stop at prototypes or SMEs that focus on niche components, Philips brings regulatory experience, global manufacturing capacity, and clinical validation infrastructure to any consortium. For project coordinators, having Philips as a partner signals industrial credibility and a realistic path to market — which strengthens any proposal's impact section.
